Venus Remedies Ltd.
Fundamentals
- Market cap
- ₹2,603 cr
- P/E
- 25.32×
- ROE
- 8.08%
- Debt / equity
- 0.00
- Div yield
- 0.54%
- 52-week range
- 416.00 — 1943.80
Company snapshot
Venus Remedies Ltd.
Pharmaceuticals
₹2,360 cr
P/E 22.96×
Latest quarter · Mar 2026
Sales₹259 cr
Net profit₹47 cr
Op. margin+24.4%
EPS₹35.52
Strength & growth
Debt / equity0.00×
Current ratio3.31×
Sales CAGR+6.6%
EPS CAGR+55.2%
The timeline — 4 notes on Venus Remedies Ltd.
May 2026
- 26 May 26 · 10:10 PM IST Brief Brief · Earnings · Small cap
Venus Remedies reports audited results and declares dividend
The company confirmed its previously disclosed annual figures and recommended a final dividend of ₹10 per share.
- 26 May 26 · 10:07 PM IST Brief Brief · Earnings · Small cap
Venus Remedies posts 89% profit jump and names new board members
The company reported a standalone net profit of ₹99.3 crore for FY26. It also appointed Saransh Chaudhary as a whole-time director.
- 26 May 26 · 9:54 PM IST Brief Brief · Earnings · Small cap
Venus Remedies profit jumps 89% as annual revenue hits ₹768.7 cr
The company reported a standalone net profit of ₹99.3 crore for FY26, up from ₹52.6 crore, and proposed a final dividend of ₹10 per share.
- 22 May 26 · 11:56 AM IST Lead Lead · Regulatory · Small cap
Venus Remedies gets first global approval for oncology drug in Saudi Arabia
The Saudi FDA's nod for Plerixafor lets Venus move from commodity drugs into higher-value oncology. Saudi Arabia is the largest Gulf pharma market.